Novartis sales and marketing update

Novartis Pharmaceuticals U.K. Ltd. launched Onbrez Breezhaler indacaterol in the U.K. to treat chronic obstructive pulmonary disease (COPD). The adrenergic receptor beta 2 (ADRB2) agonist costs L29.2...